Community Practice Connections: New Frontiers in Immuno - Oncology for Microsatellite Instability - High Cancers
WebcastFaculty
OVERVIEW
Community Practice Connections: New Frontiers in Immuno - Oncology for Microsatellite Instability - High Cancers is organized by Physicians Education Resource, LLC (PER) and will be held on Aug 31, 2017 - Aug 31, 2018.
The target audience for this medical event is directed toward medical oncologists who treat patients with solid tumors. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of solid tumors also are invited to participate. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Explain the evolving roles for MMR deficiency and MSI testing in clinical oncology practice
• Describe the relationship between MSI status and immunologic response, including evidence concerning the use of MSI as a predictive marker for response to checkpoint blockade
• Evaluate current and emerging clinical trial results concerning the use of immunotherapeutic approaches in patients with MSI-H tumors
• Delineate next steps in the field concerning the use of novel treatment strategies for the management of MSI-H cancers
Additional details will be posted as soon as they are available.
The target audience for this medical event is directed toward medical oncologists who treat patients with solid tumors. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of solid tumors also are invited to participate. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Explain the evolving roles for MMR deficiency and MSI testing in clinical oncology practice
• Describe the relationship between MSI status and immunologic response, including evidence concerning the use of MSI as a predictive marker for response to checkpoint blockade
• Evaluate current and emerging clinical trial results concerning the use of immunotherapeutic approaches in patients with MSI-H tumors
• Delineate next steps in the field concerning the use of novel treatment strategies for the management of MSI-H cancers
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links